Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Recruiting · NCT06171750 · Registry updated 2026-03-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, skin squamous cell carcinoma | Recruiting | Phase 1 | 2026-03-06 | NCT06171750 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ankyra Therapeutics, Inc | 2 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hillman Cancer Center | Pittsburgh | United States | 8 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| National Cancer Institute | Bethesda | United States | 5 |
| Princess Margaret Cancer Centre | Toronto | Canada | 145 |
| Providence Cancer Institute | Portland | United States | 17 |